Clinical Evidence: What Trials Show About Weight Loss Results
What Is Best Mounjaro or Wegovy: Understanding the Clinical Evidence
When evaluating what is best Mounjaro or Wegovy for UK weight loss results, clinical trial data provides the most reliable foundation for comparison. The STEP programme demonstrated that patients taking Wegovy alongside diet and exercise achieved approximately 15% average weight loss at 68 weeks in the landmark STEP 1 trial (Wilding et al., NEJM, 2021). Meanwhile, Mounjaro's SURMOUNT trials showed different weight loss patterns, though direct comparison isn't possible due to varying trial designs and patient populations.
Both prescription-only medicines require clinical assessment through a GPhC-registered pharmacy like EverydayMeds (#9012878) to ensure appropriate prescribing. The key difference lies in their mechanisms - Wegovy targets GLP-1 receptors exclusively, whilst Mounjaro activates both GIP and GLP-1 receptors for dual hormone action. Your prescriber can evaluate which mechanism may be more suitable based on your individual health profile and weight management goals.
Wegovy and Mounjaro Pricing: Complete UK Cost Comparison
Understanding what is best Mounjaro or Wegovy often involves practical considerations like pricing and accessibility. Wegovy starts at £79.99 for the 0.25mg starter dose (after FIRST40 discount code for new customers), progressing through £94.99 for 0.5mg, £99.99 for 1mg, £139.99 for 1.7mg, to £209.99 for the 2.4mg maintenance dose. Our Getting Started bundles like the Intro Duo (0.25mg & 0.5mg) cost £169.99, providing convenience and Reliable Supply continuity.
Returning customers benefit from the DOSE25 discount code applied at checkout, making ongoing treatment more affordable. The Ultimate Stability Trio provides three months of 2.4mg maintenance supply for £649.99, eliminating the need for multiple orders. Both Wegovy and Mounjaro follow similar escalation schedules, though their pricing structures differ due to manufacturer variations and supply considerations across the UK market.
STEP Trial Results: Evidence-Based Weight Loss Outcomes
The question of what is best Mounjaro or Wegovy for weight loss results requires examining peer-reviewed clinical evidence from major trials. In STEP 1, patients taking Wegovy alongside a reduced-calorie diet and increased physical activity achieved approximately 15% average weight loss at 68 weeks, compared to 2.4% with placebo. STEP 3 demonstrated even higher results at approximately 16% when combined with intensive behavioural therapy.
STEP 5's two-year data showed sustained weight loss of approximately 15.2%, indicating long-term effectiveness when treatment continues. The SELECT trial revealed an additional benefit: 20% reduction in major cardiovascular events, highlighting Wegovy's broader health impact beyond weight management. These results reflect clinical trial conditions and individual outcomes may vary.
How Wegovy Works: GLP-1 Mechanism for Appetite Control
When considering what is best Mounjaro or Wegovy, understanding Wegovy's mechanism helps clarify its clinical effects. Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics the natural fullness hormone released after eating. This action reduces appetite by signalling satiety to brain centres that control hunger, helping patients feel satisfied with smaller meal portions. The once-weekly injection provides consistent hormone levels throughout the week, maintaining appetite suppression between doses. Unlike Mounjaro's dual-hormone approach, Wegovy focuses specifically on GLP-1 pathways, which may suit patients who respond well to targeted appetite regulation. Clinical trials suggest this mechanism works most effectively alongside lifestyle modifications including reduced-calorie diets and increased physical activity.
EverydayMeds Ordering Process: From Assessment to Delivery
Determining what is best Mounjaro or Wegovy starts with EverydayMeds' streamlined ordering process designed for UK patients seeking prescription weight management support. The initial step involves a comprehensive 3-minute online clinical assessment covering medical history, current medications, and weight management goals to ensure safe prescribing. Our qualified prescribers review applications within 3 working days (or 24 hours with express service), evaluating suitability for either Wegovy or Mounjaro based on individual circumstances. Once approved, next-day delivery ensures rapid treatment initiation through our temperature-controlled cold-chain logistics network. The entire process maintains clinical safety standards whilst providing convenient access to prescription-only medicines through our GPhC-registered pharmacy (#9012878). Patient support continues throughout treatment with accessible prescriber guidance for dose adjustments and ongoing monitoring.
Storage and Practical Considerations: Wegovy vs Mounjaro Differences
Practical factors often influence what is best Mounjaro or Wegovy decisions, particularly regarding storage and administration convenience. Wegovy maintains stability at room temperature (below 30°C) for up to 6 weeks once removed from refrigeration, compared to Mounjaro's 21-day room temperature limit. This storage advantage benefits UK patients who travel frequently or lack consistent refrigeration access during holidays or work trips. Both treatments use pre-filled FlexTouch pens for subcutaneous injection, following identical 4-week dose escalation schedules starting from the lowest dose. Wegovy's dose progression moves through 0.25mg, 0.5mg, 1mg, 1.7mg to 2.4mg maintenance, with each step carefully designed to minimise gastrointestinal side effects whilst optimising therapeutic benefit. The prescription-only medicine status requires ongoing prescriber supervision for dose adjustments and monitoring throughout treatment duration.
UK Weight Loss Results: Real-World Effectiveness Patterns
Evaluating what is best Mounjaro or Wegovy for UK weight loss results involves understanding how clinical trial data translates to real-world outcomes in British healthcare settings. Wegovy's effectiveness appears consistent across diverse patient populations, though individual responses vary based on baseline BMI, adherence to lifestyle modifications, and genetic factors affecting GLP-1 sensitivity. The NICE recommendation (TA875) supports Wegovy use with specialist weight management programmes, suggesting optimal results require comprehensive lifestyle support beyond medication alone.
Long-term sustainability remains crucial when considering what is best Mounjaro or Wegovy, as STEP 1 extension data showed patients regained approximately two-thirds of lost weight within one year of stopping treatment. This pattern emphasises that weight management represents a long-term commitment rather than a short-term intervention. Both treatments work most effectively when patients maintain reduced-calorie diets and increased physical activity throughout the treatment period and beyond.
Making Your Decision: Prescriber Guidance and Next Steps
The final determination of what is best Mounjaro or Wegovy depends on individual clinical assessment rather than universal recommendations, as both treatments offer distinct advantages for different patient profiles. EverydayMeds prescribers evaluate factors including medical history, previous weight loss attempts, lifestyle preferences, and treatment goals to recommend the most appropriate option. New customers can begin their assessment today using discount code FIRST40, whilst returning customers benefit from DOSE25 for ongoing supplies. Our clinical team provides ongoing support throughout your weight management journey, ensuring optimal outcomes through proper dose escalation and lifestyle guidance. Start your assessment at https://everydaymeds.co.uk/collections/wegovy to discuss which treatment aligns with your individual circumstances and weight loss objectives. Remember that both Wegovy and Mounjaro are available from EverydayMeds, and your prescriber can help determine which is right for you.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
